{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:34:39Z","timestamp":1792802079690,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Canadian Institutes of Health Research (CA)","award":["DNM-137713"],"award-info":[{"award-number":["DNM-137713"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2377-x","type":"journal-article","created":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T04:29:54Z","timestamp":1491884994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses"],"prefix":"10.1186","volume":"17","author":[{"given":"Christopher","family":"Pease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Yazdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candyce","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Skidmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo G.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,11]]},"reference":[{"issue":"9","key":"2377_CR1","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","volume":"163","author":"E Corbett","year":"2003","unstructured":"Corbett E, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163(9):1009\u201321.","journal-title":"Arch Intern Med"},{"key":"2377_CR2","volume-title":"Guidelines on the management of latent tuberculosis infection","author":"World Health Organization","year":"2015","unstructured":"World Health Organization, \u201cGuidelines on the management of latent tuberculosis infection,\u201d 2015."},{"key":"2377_CR3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oxfordjournals.aje.a121593","volume":"99","author":"GW Comstock","year":"1974","unstructured":"Comstock GW, Livesay V, Woolpert S. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99:131\u20138.","journal-title":"Am J Epidemiol"},{"key":"2377_CR4","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1183\/09031936.00120908","volume":"33","author":"U Mack","year":"2009","unstructured":"Mack U, Migliori G, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. Tubercolosis? A TBNET consensus statement. Eur Respir J. 2009;33:956\u201373.","journal-title":"Eur Respir J"},{"issue":"23","key":"2377_CR5","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"T Sterling","year":"2011","unstructured":"Sterling T, Villarino M, Borisov A, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. NEJM. 2011;365(23):2155\u201366.","journal-title":"NEJM"},{"key":"2377_CR6","doi-asserted-by":"crossref","unstructured":"Villarino M, Scott N, Weiss S, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of Rifapentine and Isoniazid. JAMA Pediatr. Epub 2015\/01\/13, 2015.","DOI":"10.1001\/jamapediatrics.2014.3158"},{"issue":"6","key":"2377_CR7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","volume":"161","author":"H Stagg","year":"2014","unstructured":"Stagg H, Zenner D, Harris R, Munoz L, Lipman M, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161(6):419\u201328.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2377_CR8","first-page":"278","volume":"8","author":"BJ Marais","year":"2004","unstructured":"Marais BJ, et al. The clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature from the pre-chemotherapy era. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis. 2004;8(3):278\u201385.","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"issue":"4","key":"2377_CR9","first-page":"392","volume":"8","author":"BJ Marais","year":"2004","unstructured":"Marais BJ, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis. 2004;8(4):392\u2013402.","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"issue":"11","key":"2377_CR10","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","volume":"16","author":"H Alsdurf","year":"2016","unstructured":"Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269\u201378.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"2377_CR11","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jclinepi.2008.10.012","volume":"62","author":"M Sampson","year":"2009","unstructured":"Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol. 2009;62(9):944\u201352.","journal-title":"J Clin Epidemiol"},{"key":"2377_CR12","unstructured":"Menzies D, \u201cCanadian Tuberculosis Standards, 7th Edition,\u201d Can. Respir. J., vol. 20, 2013."},{"key":"2377_CR13","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"J Higgins","year":"2011","unstructured":"Higgins J, Altman D, Gotzsche P, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ."},{"issue":"3","key":"2377_CR14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","volume":"41","author":"RM Turner","year":"2012","unstructured":"Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane database of systematic reviews. Int J Epidemiol. 2012;41(3):818\u201327.","journal-title":"Int J Epidemiol"},{"key":"2377_CR15","unstructured":"Dias S, Welton N, Sutton A, and Ades A, \u201cNICE DSU Technical Support Document 2:A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials.,\u201d http:\/\/www.nicedsu.org.uk , 2011."},{"key":"2377_CR16","unstructured":"Dias S, Sutton A, Welton N, and Ades A, \u201cNICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-regression, bias and bias-adjustment,\u201d http:\/\/www.nicedsu.org.uk , 2012."},{"key":"2377_CR17","unstructured":"Dias S, Welton N, Sutton A, Caldwell D, Lu G, and Ades A, \u201cNICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials.,\u201d http:\/\/www.nicedsu.org.uk , 2011."},{"issue":"2","key":"2377_CR18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades A, Ioannidis J. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371.","journal-title":"J Clin Epidemiol"},{"key":"2377_CR19","doi-asserted-by":"crossref","unstructured":"Hutton B et al., \u201cThe PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Healthcare Interventions: Checklist and Explanations,\u201d Ann. Intern. Med., vol. In press, 2015.","DOI":"10.7326\/M14-2385"},{"issue":"11","key":"2377_CR20","first-page":"401","volume":"111","author":"E Martinez Alfaro","year":"2015","unstructured":"Martinez Alfaro E, et al. Compliance, tolerance and efficacy of a short course of chemoprophylaxis for tuberculosis. Med Clin Barc. 2015;111(11):401\u20134.","journal-title":"Med Clin Barc"},{"key":"2377_CR21","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/jac\/dku562","volume":"70","author":"SH Kim","year":"2015","unstructured":"Kim SH, et al. Isoniazid treatment to prevent TB in kidney and pancreas transplant recipients based on an interferon-g-releasing assay: an exploratory randomized controlled trial. J Antimicrob Chemother. 2015;70:1567\u201372.","journal-title":"J Antimicrob Chemother"},{"key":"2377_CR22","doi-asserted-by":"crossref","unstructured":"Sterling T, Moro R, Borisov A, and et al, Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT TB study. Clin Infect Dis. 2015 Epub 20150424.","DOI":"10.1093\/cid\/civ323"},{"issue":"3","key":"2377_CR23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5588\/ijtld.12.0510","volume":"17","author":"M Jimenez-Fuentes","year":"2013","unstructured":"Jimenez-Fuentes M, de Souza GM, Auge C, Solsana Peiro J, Altet-Gomez M. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. Int J Tuberc Lung Dis. 2013;17(3):326\u201332.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"2377_CR24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1078345811435973","volume":"18","author":"M White","year":"2012","unstructured":"White M, Tulsky J, Lee J, Chen L, Goldenson J, et al. Isoniazid vs. Rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. J Correct Health Care. 2012;18(2):131\u201342.","journal-title":"J Correct Health Care"},{"issue":"5","key":"2377_CR25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5588\/ijtld.11.0504","volume":"16","author":"P Chan","year":"2012","unstructured":"Chan P, et al. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. Int J Tuberc Lung Dis. 2012;16(5):633\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"2377_CR26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","volume":"365","author":"N Martinson","year":"2011","unstructured":"Martinson N, Barnes G, Moulton L, et al. New regimens to prevent tuberculosis in adults with HIV infection. NEJM. 2011;365(1):11\u201320.","journal-title":"NEJM"},{"key":"2377_CR27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","volume":"149","author":"D Menzies","year":"2008","unstructured":"Menzies D, Long R, Trajman A, Dion MJ, Yang J, et al. Adverse events with 4 months of Rifampin therapy or 9 months of Isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149:689\u201397.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2377_CR28","first-page":"551","volume":"14","author":"A Trajman","year":"2010","unstructured":"Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2010;14(5):551\u20139.","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"issue":"5","key":"2377_CR29","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1157\/13102264","volume":"25","author":"M Paloma Geijo","year":"2006","unstructured":"Paloma Geijo M, Herranz CR, Vano D, Garcia AJ, Garcia M, Dimas JF. Short course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial. Enferm Infecc Microbiol Clin. 2006;25(5):300\u20134.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2377_CR30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/520983","volume":"45","author":"N Spyridis","year":"2007","unstructured":"Spyridis N, Spyridis P, Gelesme A, Spyspa V, Valianatou M, et al. The effectiveness of a 9-month regimen of Isoniazid alone versus 3- and 4-month regimens of Isoniazid plus Rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. CID. 2007;45:715\u201322.","journal-title":"CID"},{"issue":"8","key":"2377_CR31","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","volume":"173","author":"M Schechter","year":"2006","unstructured":"Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med. 2006;173(8):922\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2377_CR32","first-page":"276","volume":"9","author":"C Tortajada","year":"2005","unstructured":"Tortajada C, Martinez-Lacasa J, Sanchez F, Jimenez-Fuentes A, de Souza M, et al. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis. 2005;9(3):276\u201381.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2377_CR33","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","volume":"170","author":"D Menzies","year":"2004","unstructured":"Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of Rifampin for 4 months versus Isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170:445\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2377_CR34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0025-7753(04)74140-8","volume":"122","author":"I Sanchez-Arcilla","year":"2004","unstructured":"Sanchez-Arcilla I, Vilchez JM, Garcia de la Torre M, Fernandez X, Noguerado A. Treatment of latent tuberculosis among homeless population. Comparison between two therapeutic approaches. Med Clin Barc. 2004;122(2):57\u20139.","journal-title":"Med Clin Barc"},{"key":"2377_CR35","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1378\/chest.124.6.2112","volume":"124","author":"C Leung","year":"2003","unstructured":"Leung C, et al. Initial experience on Rifampin and Pyrazinamide vs Isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. Chest. 2003;124:2112\u20138.","journal-title":"Chest"},{"issue":"6","key":"2377_CR36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0213-005X(03)72943-7","volume":"21","author":"J Portilla","year":"2003","unstructured":"Portilla J, Jorda P, Esteban J, Sanchez-Paya J, Merino E, et al. Directly observed treatment of latent tuberculosis infection: comparative study of two isoniazid regimens. Enferm Infec Microbiol Clin. 2003;21(6):293\u20135.","journal-title":"Enferm Infec Microbiol Clin"},{"key":"2377_CR37","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/00002030-200111090-00009","volume":"15","author":"J Johnson","year":"2001","unstructured":"Johnson J, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001;15:2137\u201347.","journal-title":"AIDS"},{"issue":"12","key":"2377_CR38","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","volume":"337","author":"C Whalen","year":"1997","unstructured":"Whalen C, Johnson J, Okwera A, Hom D, Huebner R, et al. A trial of three regimens to prevent tuberculosis in ugandan adulsts infected with the human immunodeficiency virus. NEJM. 1997;337(12):801\u20138.","journal-title":"NEJM"},{"issue":"11","key":"2377_CR39","first-page":"1043","volume":"3","author":"J Matteelli","year":"1999","unstructured":"Matteelli J, Olliaro P, Signorini L, Cadeo G, Scalzini A, et al. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. Int J Tuberc Lung Dis. 1999;3(11):1043\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"2377_CR40","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.283.11.1445","volume":"283","author":"F Gordin","year":"2000","unstructured":"Gordin F, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn community programs for clinical research on AIDS, the adult AIDS Clinical Trials Group, the pan American Health Organization, and the Centers for Disease Control and Prevention study group. JAMA. 2000;283(11):1445\u201350.","journal-title":"JAMA"},{"key":"2377_CR41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/422724","volume":"39","author":"F Gordin","year":"2004","unstructured":"Gordin F, Cohn D, Matts J, Chaisson R, O\u2019Brien R. Hepatotoxicity of Rifampin and Pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infec Dis. 2004;39:561\u20135.","journal-title":"Clin Infec Dis"},{"issue":"5","key":"2377_CR42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0025-7753(00)71496-5","volume":"115","author":"E Martinez-Alfaro","year":"2000","unstructured":"Martinez-Alfaro E, Cuadra F, Solera J, Angel Macia M, Geijo P, et al. Assessment of two chemopropyhylaxis regimens for tuberculosis in HIV-infected patients. Med Clin Barc. 2000;115(5):161\u20135.","journal-title":"Med Clin Barc"},{"key":"2377_CR43","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(97)06532-X","volume":"351","author":"N Halsey","year":"1998","unstructured":"Halsey N, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998;351:786\u201392.","journal-title":"Lancet"},{"key":"2377_CR44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0962-8479(96)90007-6","volume":"77","author":"R Cowie","year":"1996","unstructured":"Cowie R. Short course chemoprophylaxis with rifampicin, isoniazid and pyrazinamide for tuberculosis evaluated in gold miners with chronic silicosis: a double-blind placebo controlled trial. Tuberc Lung Dis. 1996;77:239\u201343.","journal-title":"Tuberc Lung Dis"},{"key":"2377_CR45","first-page":"761","volume":"48","author":"K Magdorf","year":"1994","unstructured":"Magdorf K, Arizzi-Rusche F, Geiter L, O\u2019Brien R, Wahn U. Compliance and tolerance of new antituberculotic short-term chemo-prevention regimes in childhood, a pilot study. Pneumologie. 1994;48:761\u20134.","journal-title":"Pneumologie"},{"issue":"4","key":"2377_CR46","first-page":"555","volume":"60","author":"International Union Against Tuberculosis Committee On Prophylaxis","year":"1982","unstructured":"International Union Against Tuberculosis Committee On Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555\u201364.","journal-title":"Bull World Health Organ"},{"issue":"2","key":"2377_CR47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ije\/2.2.153","volume":"2","author":"R Debre","year":"1973","unstructured":"Debre R, Perdrizet S, Lotte A, Naveau M, Lert F. Isoniazid chemoprophylaxis of latent primary tuberculosis: in five trial Centres in France from 1959 to 1969. Int J Epidemiol. 1973;2(2):153\u201360.","journal-title":"Int J Epidemiol"},{"key":"2377_CR48","first-page":"169","volume":"41","author":"G Veening","year":"1968","unstructured":"Veening G. Long term isoniazid prophylaxis: controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull Int Union Tuberc. 1968;41:169\u201371.","journal-title":"Bull Int Union Tuberc"},{"key":"2377_CR49","first-page":"419","volume":"33","author":"T Egsmose","year":"1965","unstructured":"Egsmose T, Ang-Awa J, Poti S. The use of Isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull World Health Organ. 1965;33:419\u201333.","journal-title":"Bull World Health Organ"},{"key":"2377_CR50","doi-asserted-by":"crossref","unstructured":"Park S, Lee S, Cho Y, Jeong Y, Kim H, Menzies D. A prospective cohort study of latent tuberculosis in adult close contacts of active pulmonary tuberculosispatients in Korea. Korean J Intern Med. 31(3):517\u201324.","DOI":"10.3904\/kjim.2015.095"},{"key":"2377_CR51","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s12879-015-1201-8","volume":"15","author":"IA Biraro","year":"2015","unstructured":"Biraro IA, et al. Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study. BMC Infect Dis. 2015;15:438.","journal-title":"BMC Infect Dis"},{"key":"2377_CR52","unstructured":"Belknap R et al., \u201cAdherence to Once-Weekly Self-Administered INH and Rifapentine for Latent TB: iAdhere,\u201d Conf. Retroviruses Opportunistic Infect. 2015, vol. abstract 827 LB."},{"issue":"5\u20136","key":"2377_CR53","first-page":"78","volume":"138","author":"E Langenskiold","year":"2008","unstructured":"Langenskiold E, Herrmann F, Luong B, Rochat T, Janssens JP. Contact tracing for tuberculosis and treatment for latent infection in a low incidence country. Swiss Med Wkly. 2008;138(5\u20136):78\u201384.","journal-title":"Swiss Med Wkly"},{"key":"2377_CR54","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa1214289","volume":"370","author":"G Churchyard","year":"2014","unstructured":"Churchyard G, Fielding K, Lewis J, Coetzee L, Corbett E, et al. A trial of mass Isoniazid preventive therapy for tuberculosis control. NEJM. 2014;370:301\u201310.","journal-title":"NEJM"},{"issue":"2","key":"2377_CR55","first-page":"226","volume":"8","author":"C Chee","year":"2004","unstructured":"Chee C, Teleman M, Boudville I, Do S, Wang Y. Treatment of latent TB infection for close contacts as a complementary TB control strategy in Singapore. Int J Tuberc Lung Dis. 2004;8(2):226\u201331.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"2377_CR56","first-page":"47","volume":"10","author":"P Mutlu","year":"2013","unstructured":"Mutlu P. Follow up results of latent tuberculosis infection in patients treated with anti-TNF-alpha. Nobel Med. 2013;10(1):47\u201352.","journal-title":"Nobel Med"},{"key":"2377_CR57","doi-asserted-by":"crossref","first-page":"A159","DOI":"10.1136\/thoraxjnl-2014-206260.320","volume":"69","author":"P Howlett","year":"2014","unstructured":"Howlett P, Lungu N, Owen W, Breen R, Baker L. With a low incidence of drug-induced hepatitis, should we be offering latent tb treatment to more patients over the age of 35? Thorax. 2014;69:A159\u201360.","journal-title":"Thorax"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2377-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T02:44:35Z","timestamp":1692758675000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2377-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,11]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2377"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2377-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,11]]},"article-number":"265"}}